Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease
Source: eagletribune.com
Stay updated with breaking news from Dosing Commenced. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease